Beth Crowder
Acute Care · Little Rock, ARNPI 1528052800
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,463 of the $24,542 with a category attached, or 87.5%. Boehringer Ingelheim accounts for 63.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $8,140 and has fallen 90.8% since, to $748 in 2025. Among acute care clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $250.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- Lilly USA, LLC$8K
- Dexcom, Inc.$214
- Insulet Corporation$74
- Medtronic$62
- Outset Medical Inc$27
- plus $149 from 7 others
What the payments were for
- Speaking & faculty fees$21,46387%
- Travel & lodging$1,5066%
- Food & beverage$1,5546%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 38 | $15,525 |
| Lilly USA, LLC | 20 | $8,491 |
| Dexcom, Inc. | 25 | $214 |
| Insulet Corporation | 3 | $74 |
| Medtronic | 3 | $62 |
| Outset Medical Inc | 1 | $27 |
| Rhythm Pharmaceuticals, Inc. | 1 | $26 |
| Boston Scientific | 2 | $25 |
| Sequel Med Tech, LLC | 1 | $25 |
| Bayer | 1 | $20 |
| Merck | 1 | $18 |
| Abbott | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$23,601
How this compares
$24,542 in reported general payments places this provider in the 95th percentile of 321 acute care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 496 | $527,479 |
| JardianceEmpagliflozin | 450 | $385,781 |
| MounjaroTirzepatide | 251 | $298,310 |
| TrulicityDulaglutide | 230 | $278,014 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 131 | $117,703 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $53,524 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $51,837 |
| RybelsusSemaglutide | 41 | $42,072 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $41,691 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 183 | $37,133 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $34,527 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $33,606 |
| FarxigaDapagliflozin Propanediol | 38 | $33,363 |
| Humalog Kwikpen U-100Insulin Lispro | 62 | $24,181 |
| Novolog FlexpenInsulin Aspart | 84 | $22,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $8,491 | $599,631619 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $15,525 | $420,308493 claims |
| MerckJanuvia | $18 | $19,72033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 acute care providers in Arkansas.
Other acute care in Little Rock
- Jill AveryLittle Rock$117K
- Lynn FrazierLittle Rock$106K
- Beverly BaxterLittle Rock$95K
- Diane GlendinningLittle Rock$26K
- Carmen Paniagua TorresLittle Rock$21K
- Shana KloskeLittle Rock$14K
- Debra BrentLittle Rock$9K
- Ginger HartLittle Rock$9K
- Holly TrottaLittle Rock$7K
- Katelyn LomaxLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.